119 related articles for article (PubMed ID: 16272562)
21. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55).
Harris CL; Abbott RJ; Smith RA; Morgan BP; Lea SM
J Biol Chem; 2005 Jan; 280(4):2569-78. PubMed ID: 15536079
[TBL] [Abstract][Full Text] [Related]
22. Mapping the binding domains on decay accelerating factor (DAF) for haemagglutinating enteroviruses: implications for the evolution of a DAF-binding phenotype.
Powell RM; Ward T; Goodfellow I; Almond JW; Evans DJ
J Gen Virol; 1999 Dec; 80 ( Pt 12)():3145-3152. PubMed ID: 10567645
[TBL] [Abstract][Full Text] [Related]
23. A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts.
Stuart AD; Eustace HE; McKee TA; Brown TD
J Virol; 2002 Sep; 76(18):9307-22. PubMed ID: 12186914
[TBL] [Abstract][Full Text] [Related]
24. Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding.
Karnauchow TM; Dawe S; Lublin DM; Dimock K
J Virol; 1998 Nov; 72(11):9380-3. PubMed ID: 9765493
[TBL] [Abstract][Full Text] [Related]
25. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.
Newcombe NG; Johansson ES; Au G; Lindberg AM; Barry RD; Shafren DR
J Virol; 2004 Feb; 78(3):1431-9. PubMed ID: 14722298
[TBL] [Abstract][Full Text] [Related]
26. Role of class I human leukocyte antigen molecules in early steps of echovirus infection of rhabdomyosarcoma cells.
Chevaliez S; Balanant J; Maillard P; Lone YC; Lemonnier FA; Delpeyroux F
Virology; 2008 Nov; 381(2):203-14. PubMed ID: 18823925
[TBL] [Abstract][Full Text] [Related]
27. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses.
Bergelson JM; Chan M; Solomon KR; St John NF; Lin H; Finberg RW
Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6245-8. PubMed ID: 7517044
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
Goodfellow IG; Evans DJ; Blom AM; Kerrigan D; Miners JS; Morgan BP; Spiller OB
J Virol; 2005 Sep; 79(18):12016-24. PubMed ID: 16140777
[TBL] [Abstract][Full Text] [Related]
29. Structural and functional analysis of coxsackievirus A9 integrin αvβ6 binding and uncoating.
Shakeel S; Seitsonen JJ; Kajander T; Laurinmäki P; Hyypiä T; Susi P; Butcher SJ
J Virol; 2013 Apr; 87(7):3943-51. PubMed ID: 23365426
[TBL] [Abstract][Full Text] [Related]
30. Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells.
Patel KP; Coyne CB; Bergelson JM
J Virol; 2009 Nov; 83(21):11064-77. PubMed ID: 19710132
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding.
Clarkson NA; Kaufman R; Lublin DM; Ward T; Pipkin PA; Minor PD; Evans DJ; Almond JW
J Virol; 1995 Sep; 69(9):5497-501. PubMed ID: 7543583
[TBL] [Abstract][Full Text] [Related]
32. The cryo-electron microscopy structure of feline calicivirus bound to junctional adhesion molecule A at 9-angstrom resolution reveals receptor-induced flexibility and two distinct conformational changes in the capsid protein VP1.
Bhella D; Goodfellow IG
J Virol; 2011 Nov; 85(21):11381-90. PubMed ID: 21865392
[TBL] [Abstract][Full Text] [Related]
33. More recent swine vesicular disease virus isolates retain binding to coxsackie-adenovirus receptor, but have lost the ability to bind human decay-accelerating factor (CD55).
Jimenez-Clavero MA; Escribano-Romero E; Ley V; Spiller OB
J Gen Virol; 2005 May; 86(Pt 5):1369-1377. PubMed ID: 15831949
[TBL] [Abstract][Full Text] [Related]
34. Echovirus infection of rhabdomyosarcoma cells is inhibited by antiserum to the complement control protein CD59.
Goodfellow IG; Powell RM; Ward T; Spiller OB; Almond JW; Evans DJ
J Gen Virol; 2000 May; 81(Pt 5):1393-401. PubMed ID: 10769083
[TBL] [Abstract][Full Text] [Related]
35. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry.
Shafren DR; Dorahy DJ; Ingham RA; Burns GF; Barry RD
J Virol; 1997 Jun; 71(6):4736-43. PubMed ID: 9151867
[TBL] [Abstract][Full Text] [Related]
36. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
Harris CL; Pettigrew DM; Lea SM; Morgan BP
J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
[TBL] [Abstract][Full Text] [Related]
37. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55).
Bergelson JM; Mohanty JG; Crowell RL; St John NF; Lublin DM; Finberg RW
J Virol; 1995 Mar; 69(3):1903-6. PubMed ID: 7531780
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of virus-host cell interactions of haemagglutinating and non-haemagglutinating strains of coxsackievirus B3.
Pasch A; Küpper JH; Wolde A; Kandolf R; Selinka HC
J Gen Virol; 1999 Dec; 80 ( Pt 12)():3153-3158. PubMed ID: 10567646
[TBL] [Abstract][Full Text] [Related]
39. Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate.
Milstone AM; Petrella J; Sanchez MD; Mahmud M; Whitbeck JC; Bergelson JM
J Virol; 2005 Jan; 79(1):655-60. PubMed ID: 15596863
[TBL] [Abstract][Full Text] [Related]
40. Echoviruses bind heparan sulfate at the cell surface.
Goodfellow IG; Sioofy AB; Powell RM; Evans DJ
J Virol; 2001 May; 75(10):4918-21. PubMed ID: 11312365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
